Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2473–2496 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension, Elevated Intraocular Pressure
Interventions: ALZ-1101, Latanoprost; Drug
Lead sponsor: Alleanza Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Morrow, Georgia

Conditions: Pulmonary Arterial Hypertension
Interventions: Bosentan, Placebo, Sildenafil Citrate; Drug · Other
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 6
States / cities: Los Angeles, California • Detroit, Michigan • Pittsburgh, Pennsylvania + 2 more

Conditions: Obesity, Pre-hypertension, Hypertension
Interventions: L-citrulline supplementation, Whole Body Vibration Training; Dietary Supplement · Other
Lead sponsor: Florida State University; Other
Eligibility: 50 Years to 70 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Hypertension
Interventions: mHealth for Hypertension in Homeless Persons; Behavioral
Lead sponsor: George Washington University; Other
Eligibility: 21 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Pulmonary Vascular Disease, Pulmonary Arterial Hypertension
Interventions: Not listed
Lead sponsor: New York Medical College; Other
Eligibility: 1 Day to 21 Years
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2031
U.S. locations: 13
States / cities: Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more

Conditions: Portopulmonary Hypertension
Interventions: Ambrisentan; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 6
States / cities: La Jolla, California • Jacksonville, Florida • Boston, Massachusetts + 3 more

Conditions: Intraocular Pressure, Glaucoma, Ocular Hypertension
Interventions: 0.01% bimatoprost; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 40 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Glaucoma, Open-Angle, Eye Diseases
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Columbus, Ohio

Conditions: Hypertension
Interventions: Spironolactone, Chlorthalidone, Diet, Placebo; Drug · Dietary Supplement
Lead sponsor: Vanderbilt University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Glaucoma
Interventions: Rocklatan, Systane Ultra; Drug
Lead sponsor: Colorado Ophthalmology Associates PC; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Timeline: 2025
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Depression, Hypertension, Hypercholesterolemia
Interventions: Cognitive behavioral therapy; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 55 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cardiovascular Disease Risk Reduction, Chronic Stress, Anxiety, Emotional Regulation, Hypertension Prevention, Health Disparities
Interventions: HRV Biofeedback Training; Behavioral
Lead sponsor: Amelia Saul, PhD, CTRS, BCB; Other
Eligibility: 18 Years to 35 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: High Blood Pressure
Interventions: Salt pills, Placebo pills; Dietary Supplement
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: High Blood Pressure
Interventions: Home Blood Pressure Machine, 24-Hour Blood Pressure Machine; Device
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 13 Years to 18 Years
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hypertension
Interventions: Salt loading, Hydrochlorothiazide (HCTZ); Procedure · Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Lancaster, Pennsylvania

Conditions: Glaucoma, Ocular Hypertension, Eye Disease
Interventions: AMA0076, Placebo; Drug
Lead sponsor: Amakem, NV; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Artesia, California • Inglewood, California • Petaluma, California + 3 more

Conditions: Visual Pathway Disorder, Glaucoma, Retinal Disease
Interventions: virtual visual field; Device
Lead sponsor: New York City Health and Hospitals Corporation; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: AGN-210669, bimatoprost, bimatoprost vehicle; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution, Netarsudil 0.02% Ophthalmic Solution, Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, AR-17043 Vehicle; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 25
States / cities: Dothan, Alabama • Phoenix, Arizona • Garden Grove, California + 20 more

Conditions: Glaucoma, Hypertension, Glaucoma, Suspect, Elevated Blood Pressure
Interventions: Virtual Automated Navigator Intervention with Health Education, Usual Care; Other
Lead sponsor: Columbia University; Other
Eligibility: 40 Years and older
Enrollment: 7,085 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma, Ocular Hypertension
Interventions: Preservative free tafluprost opthalmic solution; Drug
Lead sponsor: Santen Oy; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: East Meadow, New York

Conditions: Glaucoma, Glaucoma, Open-Angle, Optic Nerve Diseases
Interventions: Repetitive, Transorbital Alternating Current Stimulation (rtACS); Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Preeclampsia Severe, Pre-Eclampsia, Preeclampsia, Preeclampsia Second Trimester, Preeclampsia Complicating Childbirth, Preeclampsia Puerperium, Preterm
Interventions: Metformin, Esomeprazole; Drug
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Newark, Delaware

Search by objective public record fields.

Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost

Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension

Whole Body Vibration Combined With L-citrulline Supplementation on Cardiovascular Function and Body Composition

Uncontrolled Hypertension Among the Homeless

Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry

Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial

24-hour IOP-lowering Effect of 0.01% Bimatoprost

The Flashing Light-Induced Pupil Response (FLIPR) Glaucoma Study

Tissue Sodium in Pre-hypertensive Patients

Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment

Biological CVD Risk Factors in Older Depressed Patients

Improving Minority Health Through Biofeedback and Stress Reduction

Salt and Gut Study

Home BP Monitoring

Salt Loading and Thiazide Intervention Study

Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma

Assessment of Visual Function in Ophthalmic Disorders Using Virtual Visual Field Analysis

Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

Next Generation Rocklatan

Know Your Pressures NYC

A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension

Comparison of Critical Flicker Fusion Versus Automated Visual Fields in the Detection of Early Glaucoma

Electrical Stimulation for the Treatment of Optic Neuropathies

Metformin and Esomeprazole in Preterm Pre-eclampsia